Roche agreed to acquire PathAI in a deal potentially worth up to $1.05 billion, aiming to accelerate the rollout of AI-powered diagnostic tools within Roche Diagnostics. The acquisition includes a $750 million upfront payment and additional milestone payments of up to $300 million, and is expected to close in the second half of 2026 subject to regulatory approvals. Roche will fold PathAI into its Diagnostics division to scale PathAI’s Image Management System and workflow capabilities globally. The companies also cited their prior collaboration, including work on AI-enabled companion diagnostic algorithms, with PathAI’s platform supporting clinical trial analytics and translational research workflows. The move aligns with a broader push to industrialize digital pathology as an operational layer for precision oncology, potentially enabling faster biomarker development and more scalable diagnostic decision support across pharma partners.